Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: Tucatinib in Combination of Oral VP16 and trastuzumab
Sponsor: Institut Curie
Collaborators: Seagen Inc.